CLAIMS

1. Use of a topical composition formulated with liposomes comprising cannabidiol (CBD) and, optionally, one or more additional cannabinoids in the preparation of a medicament for improving female sexual function and/or treating a female sexual disorder, wherein: the medicament is adapted for application to a female subject's genital (arousal) area(s); and the medicament is adapted for application to mucosal surface in an amount and for a period of time prior to a sexual activity for enhancement of sexual function of the subject and/or for ameliorating the disorder during the sexual activity.

2. The use of claim 1, wherein the genital area includes genitalia with absorptive mucosa, comprising one or more of: introitus, vulva, labia minora, clitoris and vaginal vault.

3. The use of claim 1, wherein the enhancement of sexual function and/or the ameliorating the disorder is exhibited by one or both of the following parameters:

i. vaginal and clitoral smooth muscle relaxation; and

ii. increased vaginal and clitoral blood flow.

4. The use of claim 1, wherein the enhancement of sexual function and/or the ameliorating the disorder is exhibited by one or more of the following subjectively self-reported outcomes including:

i. “increased lubrication/wetness during sexual activity”;

ii. “reaching orgasm more often”;

iii. “greater ease or achieving orgasm”;

iv. “being more satisfied”;

v. “higher level of sexual desire”; and

vi. “reduction in pain during sexual activity”.

5. The use of claim 1, wherein the subject is premenopausal.

6. The use of claim 4, wherein the outcomes reported by post-menopausal women are similar to those reported by premenopausal women with respect to one or more of the following:

i. improved arousal;

ii. improved lubrication; and

iii. improved ease of achieving orgasm.

7. The use of claim 1, wherein the total amount of CBD comprised in the topical composition is from 5 mg to 1,000 mg of CBD; 10-100 mg of CBD; or 20-40 mg of CBD.

8. The use of claim 1, wherein the period of time is 5-30 mins prior to the sexual activity.

9. The use of claim 1, where the additional cannabinoid(s) is/are selected from the group consisting of Δ^9-THC, Δ^8-THC, CBD, and CBN.

10. The use of any of the preceding claims, where CBD is hemp-derived and/or contain less 0.3% THC by weight.

11. The use of claim 1, wherein the topical composition is provided in a single-use container.

12. The use of claim 1, wherein the topical composition further comprises preservative(s) and is provided in a multi-use container.

13. The use of claim 1, wherein the topical composition is compatible with latex and polyisoprene condoms.

14. The use of claim 1, wherein the medicament is pre-coated on a condom.

15. The use of claim 1, wherein the concentration of CBD comprised in the topical composition is from 1 mg/ml to 40 mg/ml; 5 mg/ml to 20 mg/ml; or 10 mg/ml.

16. The use of claim 1, wherein the topical composition comprises liposomes that comprise HSPC, ascorbic acid, sodium ascorbate, propylene glycol, polyacrylate crosspolymer-6, and water or aqueous buffer, and wherein the liposomes are provided in a homogeneous suspension.

17. The use of claim 1, wherein the period of time is 1-60 min; 5-40 min; or 15-20 min.

18. The use of claim 1, wherein the subject is afflicted with a disorder selected from: (1) Sexual Interest/Arousal Disorder (SIAD); and (2) Female Orgasmic Disorder.

19. The use of claim 1, wherein the topical composition further comprises a phosphodiesterase type 5 inhibitor.

20. The use of claim 19, wherein the inhibitor is chosen from sildenafil, tadalafil, vardenafil, and udenafil.

21. The use of claim 1, wherein the topical composition further comprises another direct smooth muscle relaxant.

22. The use of claim 21, wherein the relaxant is chosen from prostaglandin E1, papaverine, and minoxidil.

23. The use of claim 1, wherein the topical composition further comprises an alpha-blocker.

24. The use of claim 23, wherein the alpha-blocker is phentolamine.

25. The use of claim 1, wherein the topical composition further comprises flibanserin.

26. The use of claim 1, wherein the topical composition further comprises bremelanotide.